Librela 10mg

Librela 10mg Solution for Injection for Dogs – Advanced Monthly Pain Relief for Osteoarthritis

Librela (bedinvetmab) is a groundbreaking prescription-only veterinary monoclonal antibody therapy specifically designed to control pain associated with osteoarthritis (OA) in dogs. Manufactured by Zoetis, this innovative injectable solution targets nerve growth factor (NGF) to provide effective, long-lasting pain relief without the daily administration required by traditional oral medications.

Available in a convenient pack of 2 x 1ml vials at 10mg strength, Librela 10mg is ideal for dogs weighing between 10.1kg and 20kg. It is administered as a simple subcutaneous injection once a month under veterinary supervision, helping dogs regain mobility, comfort, and quality of life.

Key Features

• Monoclonal Antibody Technology: Contains bedinvetmab, a canine-specific monoclonal antibody that selectively binds to and neutralizes nerve growth factor (NGF).
• Monthly Convenience: One subcutaneous injection every 4 weeks – perfect for dogs that are difficult to medicate daily.
• Targeted Pain Relief: Works differently from NSAIDs by blocking pain signaling pathways rather than reducing inflammation systemically.
• Improved Mobility: Helps reduce stiffness, limping, and reluctance to exercise, stairs, or jumping.
• Prescription Only: Requires a valid veterinary prescription and is typically administered by a vet.
• Refrigerated Storage: Must be stored in a refrigerator and handled with care during shipping.

How Librela Works

In dogs with osteoarthritis, elevated levels of nerve growth factor (NGF) amplify pain signals from affected joints to the brain. Bedinvetmab, the active ingredient in Librela, is a laboratory-engineered canine monoclonal antibody that binds specifically to NGF. By neutralizing NGF, Librela reduces the transmission of pain signals, providing relief from the chronic discomfort of osteoarthritis.

Unlike traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as meloxicam or carprofen, Librela does not inhibit cyclooxygenase enzymes. This makes it a valuable alternative or complementary option for dogs that cannot tolerate long-term NSAID use or require additional targeted analgesia.

Indications

Librela is indicated for the alleviation of pain associated with osteoarthritis in dogs. Common signs of OA that may improve with treatment include:

• Stiffness after rest (especially in the morning)
• Reluctance to climb stairs, jump into the car, or get onto furniture
• Limping or altered gait
• Reduced activity, shorter walks, or lagging behind
• Licking of joints or sensitivity when handled
• Changes in mood or exercise tolerance

Dosage & Administration

The recommended dose is 0.5–1.0 mg/kg body weight, administered subcutaneously once a month. For dogs weighing 10.1–20kg, the full content of one 10mg (1ml) vial is typically used.

Important:

• Must be given by or under the direction of a licensed veterinarian.
• Administer the entire contents of the vial(s) as a single subcutaneous injection.
• Do not shake the vial vigorously.
• Use immediately after withdrawal into a syringe.
• Response may be noticeable within the first month; some dogs require a second injection before full benefit is observed.

Benefits for Your Dog

• Consistent monthly pain control without daily pills
• Supports better mobility and willingness to exercise
• May reduce reliance on daily oral pain medications
• Particularly useful as part of a multimodal osteoarthritis management plan (alongside weight control, controlled exercise, joint supplements, and environmental modifications)

Important Safety Information

Contraindications: Do not use in dogs with known hypersensitivity to bedinvetmab or any of the excipients. Do not use in breeding, pregnant, or lactating dogs. Not recommended for dogs under 12 months of age.

Possible Side Effects: Most dogs tolerate Librela well. Reported adverse events include:

• Injection site reactions (swelling, warmth)
• Lethargy, reduced appetite
• Digestive upset (vomiting, diarrhoea)
• Increased thirst or urination, urinary incontinence
• Rare neurological signs such as ataxia (wobbliness) or, very rarely, seizures

Contact your veterinarian immediately if your dog shows any unusual signs after injection. Always discuss the benefits and risks with your vet before starting treatment.

Storage

Store in a refrigerator (2–8°C). Do not freeze. Protect from light. Once removed from the refrigerator, use promptly.

Librela is a prescription-only medicine. A valid veterinary prescription is required. This product is intended for veterinary use only and should form part of a comprehensive osteoarthritis management plan under professional guidance.